UNASSIGNED: 29 Background: The current standard of care for @entity5 for @entity1 who can withstand aggressive therapy is chemotherapy, radiotherapy and surgery (tri-modality therapy). This is the largest study of its kind to date. METHODS: Using the National @entity5 Database (NCDB) 46,758 @entity1 diagnosed with @entity5 between 2000 and 2009 were identified. The NCDB database includes data from 70% of @entity5 @entity1 in the US. RESULTS: In @entity5 private insurance holders received more tri-modality therapy (39%) than @entity22066 insurance (18%), Medicaid (22%), Medicare (18%), and the uninsured (19%) (p<0.0001). There was no statistically significant difference in the amount of tri-modality therapy received in @entity1 with @entity22066 , Medicare, or no insurance. Medicaid @entity1 received more tri-modality therapy than Medicare, uninsured, and @entity22066 @entity1 (p<0.05). @entity22066 and uninsured @entity1 received no treatment more frequently (13%) than those with private insurance (5%), Medicare (10%), and Medicaid (9%) (p<0.0003). @entity1 over 70 less frequently underwent tri-modality therapy (13%) as compared to those under 70 (34%, p<0.0001). CONCLUSIONS: Although @entity22066 , Medicare, and the uninsured @entity1 received similar rates of tri-modality therapy (18-19%), it was much less than private insurance holders (39%). Medicaid @entity1 received less tri-modality therapy than private insurance holders despite similar ages. Uninsured @entity1 received a similar amount of tri-modality therapy as those with @entity22066 and Medicare. [Table: see text].

Surgery and chemoradiotherapy in XXXX : A retrospective analysis of first-course treatment across different insurances using the NCDB.

@entity5 :: ('MESH:D009369', 'Disease') :: ['stage II/III esophageal carcinoma', 'cancer', 'stage II/III esophageal cancer', 'Cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity22066 :: ('MESH:C563443', 'Disease') :: ['VA']
@entity5 :: (MESH:D009369,Disease) :: ['stage II and III esophageal cancer']
